Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective = Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

다국어 초록 (Multilingual Abstract)

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a major cause of liver fibrosis and cirrhosis. Accurate assessment of liver fibrosis is important for predicting disease outcomes and assessing therapeutic response in clinical practice and clinical trials. Although noninvasive tests such as transient elastography and magnetic resonance elastography are preferred where possible, histological assessment of liver fibrosis via semiquantitative scoring systems remains the current gold standard. Collagen proportionate area provides more granularity by measuring the percentage of fibrosis on a continuous scale, but is limited by the absence of architectural input. Although not yet used in routine clinical practice, advances in second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy imaging show great promise in characterising architectural features of fibrosis at the individual collagen fiber level. Quantification and calculation of different detailed variables of collagen fibers can be used to establish algorithm-based quantitative fibrosis scores (e.g., qFibrosis, q-FPs), which have been validated against fibrosis stage in NAFLD. Artificial intelligence is being explored to further refine and develop quantitative fibrosis scoring methods. SHG-microscopy shows promise as the new gold standard for the quantitative measurement of liver fibrosis. This has reaffirmed the pivotal role of the liver biopsy in fibrosis assessment in NAFLD, at least for the near-future. The ability of SHG-derived algorithms to intuitively detect subtle nuances in liver fibrosis changes over a continuous scale should be employed to redress the efficacy endpoint for fibrosis in NASH clinical trials; this approach may improve the outcomes of the trials evaluating therapeutic response to antifibrotic drugs. (Clin Mol Hepatol 2021;27:44-57)

참고문헌 (Reference)

• 1 Xu S, "qFibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients" 61 : 260-269, 2014
• 2 Liu F, "qFIBS:an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis" 71 : 1953-1966, 2020
• 3 Ratziu V, "Why do so many NASH trials fail?" 046-, 2020
• 4 Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease" 60 : 565-575, 2014
• 5 Mann DA, "Transcriptional regulation of hepatic stellate cell activation" 50 : 891-896, 2002
• 6 Angulo P, "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD" 45 : 846-854, 2007
• 7 Brunt EM, "Steatohepatitis Clinical Research Network. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials" 70 : 522-531, 2019
• 8 Pai RK, "Standardising the interpretation of liver biopsies in nonalcoholic fatty liver disease clinical trials" 50 : 1100-1111, 2019
• 9 Liu F, "Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease" 148 : 502-512, 2017
• 10 Chang PE, "Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease" 13 : e0199166-, 2018
• 11 Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C" 38 : 1449-1457, 2003
• 12 Ratziu V, "Sampling variability of liver biopsy in nonalcoholic fatty liver disease" 128 : 1898-1906, 2005
• 13 Hall AR, "Sample size requirement for digital image analysis of collagen proportionate area in cirrhotic livers" 62 : 421-430, 2013
• 14 Chávez-Tapia NC, "Role of nonalcoholic fatty liver disease in hepatocellular carcinoma" 8 (8): S34-S39, 2009
• 15 Hammoutene A, "Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease" 70 : 1278-1291, 2019
• 16 Loomba R, "Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions" 68 : 296-304, 2018
• 17 Karsdal MA, "Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar" 40 : 233-249, 2014
• 18 Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease" 대한간학회 25 (25): 1-11, 2019
• 19 Urasaki Y, "Quantitative assessment of liver steatosis and affected pathways with molecular imaging and proteomic profiling" 8 : 3606-, 2018
• 20 Masugi Y, "Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease" 2 : 58-68, 2017
• 21 Wanless IR, "Quantitative SHG-microscopy: unraveling the nanoarchitecture of the cirrhotic liver" 44 : 1-3, 2020
• 22 Wang Y, "Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy" 69 : 1116-1126, 2020
• 23 Theise ND, "Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification" 31 : 1191-1200, 2018
• 24 Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis" 4 : 389-398, 2019
• 25 Nakayama H, "Presence of perivenular elastic fibers in nonalcoholic steatohepatitis fibrosis stage III" 23 : 407-409, 2008
• 26 Lin B, "Novel serum biomarkers for noninvasive diagnosis and screening of nonalcoholic fatty liver disease-related hepatic fibrosis" 23 : 181-189, 2019
• 27 Sun W, "Nonlinear optical microscopy: use of second harmonic generation and twophoton microscopy for automated quantitative liver fibrosis studies" 13 : 064010-, 2008
• 28 Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers" 47 : 455-460, 2008
• 29 Tapper EB, "Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD" 15 : 274-282, 2018
• 30 Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease" 156 : 1264-1281.e4, 2019
• 31 Brunt EM, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions" 94 : 2467-2474, 1999
• 32 Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates" 17 : 748-755.e3, 2019
• 33 Brunt EM, "Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation" 1 : 370-378, 2017
• 34 Brunt EM, "Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings" 53 : 810-820, 2011
• 35 Castera L, "Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics" 40 (40): 77-81, 2020
• 36 Sun Y, "New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment" 65 : 1438-1450, 2017
• 37 Fassio E, "Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies" 40 : 820-826, 2004
• 38 Liou I, "Natural history of nonalcoholic steatohepatitis" 40 (40): S11-S16, 2006
• 39 McDonald N, "Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study" 8 : 9189-, 2018
• 40 Banerjee R, "Multiparametric magnetic resonance for the noninvasive diagnosis of liver disease" 60 : 69-77, 2014
• 41 Pirola CJ, "Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity" 24 : 1601-1615, 2018
• 42 Fuchs BC, "Molecular MRI of collagen to diagnose and stage liver fibrosis" 59 : 992-998, 2013
• 43 Schwabe RF, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis" 158 : 1913-1928, 2020
• 44 Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease" 152 : 598-607.e2, 2017
• 45 Baiocchini A, "Liver sinusoidal endothelial cells (LSECs) modifications in patients with chronic hepatitis C" 9 : 8760-, 2019
• 46 Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease" 149 : 389-397.e10, 2015
• 47 Li S, "Liver fibrosis conventional and molecular imaging diagnosis update" 8 : 236-, 2019
• 48 Friedman SL, "Liver fibrosis -- from bench to bedside" 38 (38): S38-S53, 2003
• 49 Poynard T, "Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis" 10 : 657-663.e7, 2012
• 50 Hall Z, "Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease" 65 : 1165-1180, 2017
• 51 Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis" 65 : 1557-1565, 2017
• 52 Colloredo G, "Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease" 39 : 239-244, 2003
• 53 Hardy T, "Imaging-based assessment of steatosis, inflammation and fibrosis in NAFLD" 16 : 298-307, 2017
• 54 Decaris ML, "Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood" 65 : 78-88, 2017
• 55 Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients" 56 : 1751-1759, 2012
• 56 Kleiner DE, "Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children" 20 : 293-312, 2016
• 57 Forlano R, "High-throughput, machine learning-based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease" 18 : 2081-2090.e9, 2020
• 58 Feldstein AE, "Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease" 3 : 384-389, 2005
• 59 Washington K, "Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver" 31 : 822-828, 2000
• 60 Trautwein C, "Hepatic fibrosis:concept to treatment" 62 (62): S15-S24, 2015
• 61 Loomba R, "Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease" 25 : 1054-1062.e5, 2017
• 62 Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes" 64 : 73-84, 2016
• 63 Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up" 61 : 1547-1554, 2015
• 64 Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD" 67 : 1265-1273, 2017
• 65 Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies" 13 : 643-654, 2015
• 66 Goldstein NS, "Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens" 123 : 382-387, 2005
• 67 Kaswala DH, "Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016" 61 : 1356-1364, 2016
• 68 Gailhouste L, "Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis" 52 : 398-406, 2010
• 69 Ooi GJ, "Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients" 2020
• 70 Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis" 54 : 344-353, 2011
• 71 Kanta J, "Elastin in the liver" 7 : 491-, 2016
• 72 Vuppalanchi R, "Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease" 7 : 481-486, 2009
• 73 Salarian M, "Early detection and staging of chronic liver diseases with a protein MRI contrast agent" 10 : 4777-, 2019
• 74 European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease" 64 : 1388-1402, 2016
• 75 Wang Y, "Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis" 65 : 1891-1903, 2017
• 76 Wattacheril J, "Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis" 8 : e57165-, 2013
• 77 Younossi ZM, "Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis" 68 : 349-360, 2018
• 78 Bedossa P, "Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: why liver biopsy is essential" 38 (38): 64-66, 2018
• 79 Ampuero J, "Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis" 18 : 216-225.e5, 2020
• 80 Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" 41 : 1313-1321, 2005
• 81 Yu Y, "Deep learning enables automated scoring of liver fibrosis stages" 8 : 16016-, 2018
• 82 Pirhonen J, "Continuous grading of early fibrosis in nafld using label-free imaging: a proof-of-concept study" 11 : e0147804-, 2016
• 83 Calvaruso V, "Computer-assisted image analysis of liver collagen:relationship to Ishak scoring and hepatic venous pressure gradient" 49 : 1236-1244, 2009
• 84 Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease" 7 : 1104-1112, 2009
• 85 Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a metaanalysis" 66 : 1486-1501, 2017
• 86 Tsochatzis E, "Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis" 60 : 948-954, 2014
• 87 Buzzetti E, "Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease" 49 : 1214-1222, 2019
• 88 Nascimbeni F, "Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease" 72 : 828-838, 2020
• 89 Sanyal AJ, "Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop" 61 : 1392-1405, 2015
• 90 Bedossa P, "Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease" 150 : 1811-1822.e4, 2016
• 91 Gawrieh S, "Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD" 47 : 151518-, 2020
• 92 Shiha G, "Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update" 11 : 1-30, 2017
• 93 Xinrong Zhang, "Application of transient elastography in nonalcoholic fatty liver disease" 대한간학회 26 (26): 128-141, 2020
• 94 Younossi ZM, "An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease" 16 : 170-, 2018
• 95 Standish RA, "An appraisal of the histopathological assessment of liver fibrosis" 55 : 569-578, 2006
• 96 Guilbert T, "A robust collagen scoring method for human liver fibrosis by second harmonic microscopy" 18 : 25794-25807, 2010
• 97 Caussy C, "A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease" 10 : 1406-, 2019